合并纤维肌痛对中轴型脊柱关节炎患者肿瘤坏死因子α阻断剂疗效影响的评估:一项前瞻性多中心研究结果
这项前瞻性多中心观察性研究纳入508例启动肿瘤坏死因子α阻断剂治疗的中轴型脊柱关节炎成人患者,基线时192例(37.8%)经纤维肌痛快速筛查工具筛查为纤维肌痛。治疗12周后,纤维肌痛组在多数疗效终点成功率较低(如BASDAI 50:45.3% vs 54.1%),但C反应蛋白变化终点组间无差异。研究结论认为纤维肌痛的存在似乎对肿瘤坏死因子α阻断剂反应有负面影响,且这种影响似乎更多与自我报告评估工具相关,而非药物在该亚组中的治疗效果不同。
要点
- 508例中轴型脊柱关节炎患者中192例(37.8%)基线筛查为纤维肌痛。
- 治疗12周后纤维肌痛组BASDAI 50成功率45.3% vs 无纤维肌痛组54.1%。
- C反应蛋白变化终点在两组间无差异。
核心结论
- 研究证实纤维肌痛在中轴型脊柱关节炎患者中共存,其存在似乎对肿瘤坏死因子α阻断剂反应有负面影响,且似乎更多与自我报告评估工具相关,而非药物在该亚组中的治疗效果不同。
研究设计与样本
- 前瞻性观察性研究,两次访视间隔3个月,纳入启动肿瘤坏死因子α阻断剂治疗的中轴型脊柱关节炎成人患者,主要分析共508例。
- 纤维肌痛分别由基线纤维肌痛快速筛查工具阳性、两次访视持续阳性及符合1990年美国风湿病学会纤维肌痛分类标准来定义。
主要发现
- 508例中192例(37.8%)基线经纤维肌痛快速筛查工具筛查为纤维肌痛。
- 治疗12周后纤维肌痛组多数疗效终点成功率较低,如BASDAI 50在纤维肌痛组为45.3%、无纤维肌痛组为54.1%(依据纤维肌痛快速筛查工具分组)。
- C反应蛋白变化终点在组间无差异。
关键数值与推荐
- 主要终点为BASDAI 50,分析时对已知影响肿瘤坏死因子α阻断剂反应的因素进行了校正。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the prevalence of fibromyalgia (FM) in an axial spondyloarthritis (axSpA) population and to confirm that concomitant FM had a negative impact on tumour necrosis factor blockers' (TNFb) response. DESIGN: Prospective observational study with two visits 3 months apart. PATIENTS: Adult patients with AxSpa initiating a TNFb. STUDY GROUPS: FM was defined by the Fibromyalgia Rapid Screening Tool (FiRST) at baseline and also by a sustained positive FiRST (both visits) and by a fulfilment of the 1990 American College of Rheumatology criteria for FM. STATISTICAL ANALYSIS: Prevalence of FM; evaluation of the impact of a concomitant FM on TNFb response (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50) as primary endpoint), adjusted by factors known to have an impact on TNFb response. RESULTS: Among the 508 patients included in the main analysis, 192 (37.8%) were screened at baseline as FM. Percentage of success after 12 weeks of treatment was lower in the FM group for most of the effectiveness endpoints (eg, BASDAI 50: 45.3% vs 54.1% in the FM/not FM groups according to the FiRST), except for the C reactive protein change endpoints which were not different across groups. CONCLUSION: This study confirms that FM coexists in patients with axSpA and that its presence seems to have a negative impact on TNFb response, which seems more related to the self-reported instruments used in its evaluation, rather than a different treatment effect of the molecule in this subgroup of patients.
引用
- Moltó A, Etcheto A, Gossec L, et al. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis. 2017. PMID: 29183878. doi:10.1136/annrheumdis-2017-212378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。